Hongbo Lu, Ph.D., is a partner of Vivo Capital. Dr. Lu brings nearly 20 years of healthcare investment experience in both public securities and private companies. Prior to joining Vivo, she served as a managing partner at Lilly Asia Ventures (LAV). She also served as a managing director at OrbiMed Advisors. During her investment career, Dr. Lu has invested extensively in both China and the U.S.
She previously served on the boards of Turning Point Therapeutics (TPTX), CrownBio (6554.TT, acquired by JSR), Avedro (AVDR, acquired by Glaukos), and Passage (PASG, observer). Dr. Lu has been extensively involved in the company incubations of ADARx, Alpiscience, Geneception, Perfuse, Terns, and Ronovo since their inception. Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. after having first worked in biotech start-ups in the Bay Area.
Dr. Lu earned a Ph.D. in bioengineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University.